Jordan

Jordan has a highly restrictive controlled-drugs environment for classical psychedelics and related substances. Current official scheduling material from the Jordan Food and Drug Administration indicates that psychotropic substances remain listed in national schedules, and a 2026 import guideline refers to narcotic substances, psychotropic agents and chemical precursors under Law No.

Ask Blossom about this country

Key Insights

A concise read of the policy, research, and stakeholder signals shaping psychedelic medicine in Jordan.

1
Jordan's public regulatory record is oriented towards control and import oversight, not therapeutic psychedelic access.
2
The visible research footprint is largely ketamine-based and hospital-linked, rather than psychedelic-specific.
3
Published Jordanian studies suggest some clinical familiarity with ketamine, but they do not establish a legal patient-access pathway outside research or standard hospital use.
4
The national ecosystem appears to involve a small number of institutions rather than a broad network of psychedelic stakeholders.
5
Recent policy signals point to continued tightening or formalisation of controlled-substance governance rather than liberalisation.

Research Snapshot

Blossom currently tracks 1 psychedelic clinical trial connected to Jordan.

Active trials: 0
Total trials: 1
Stakeholders: 1
Events: 0

Top Compounds

Psilocybin(1)

Medical Access Snapshot

Jordan maintains a highly restrictive national drug control regime: most classical psychedelics (psilocybin, MDMA, DMT, mescaline, 5-MeO-DMT, ibogaine, ayahuasca, 2C-X) are treated as controlled/psychotropic substances with criminal penalties and no routine medical reimbursement or authorized clinical treatment access. Ketamine is used within Jordanian healthcare primarily as an anaesthetic in hospitals (medical use), but psychedelic or psychiatric uses are off-label and not publicly reimbursed; esketamine (Spravato) has no public record of local...

View trials→View stakeholders→Open access guide→

Regulatory Status

Access appears strict: official Jordanian materials show psychotropic substances are scheduled, and recent regulatory guidance continues to frame import and handling through controlled-substances law. I did not find a public, authoritative source showing routine legal access pathways for psilocybin, MDMA, DMT, mescaline, 5-MeO-DMT, ibogaine or ayahuasca; based on the available evidence, non-trial access looks effectively prohibited, while ketamine is used in ordinary medical care but psychedelic or psychiatric use remains off-label and not clearly reimbursed. This last point is an inference from the limited public record rather than an explicit reimbursement statement.